



MARKET RELEASE

2 March 2018

LBT Innovations Limited

TRADING HALT

The securities of LBT Innovations Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 6 March 2018 or when the announcement is released to the market.

Security Code: LBT

Christopher Dobbs

ADVISER, LISTINGS COMPLIANCE (SYDNEY)

2 March 2018

The Manager
Company Announcements Office
ASX Limited

TRADING HALT REQUEST

LBT Innovations Limited (ASX:LBT) requests a trading halt be put on its securities immediately pending an announcement in relation to a capital raising to the market.

LBT Innovations Limited can see no reason why a trading halt should not be put on its securities.

The trading halt is expected to be lifted by no later than before commencement of trading on Tuesday 6th March 2018 following an announcement of the capital raising.

Yours sincerely,



Dan Hill
Company Secretary

– ENDS –

About LBT Innovations

LBT Innovations (LBT) uses artificial intelligence (AI) to improve patient outcomes, making healthcare more efficient. The company has developed a patent protected machine learning and intelligent imaging platform technology to deliver the only FDA cleared instrument utilising AI technology in clinical microbiology. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and the Automated Plate Assessment System (APAS®). LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT has extended its core FDA Cleared AI technology in the area of chronic wound management. WoundVue® is prototype hand-held device which automatically analyses and records progress of long-term chronic wounds.

CONTACTS

LBT Innovations	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	Sarah Kemter Monsoon Communications Tel: +61 3 9620 3333 E: sarahk@monsoon.com.au